Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
See this aricle in Pubmed

Article Abstract
Despite the US Food and Drug Administrations approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.
 
Related Tags
(click to filter results - removes previous filter)

cerebrovascular accident
cerebrovascular accident,acute management of
cerebrovascular accident,thrombolytic agents in treatment
diagnosis related group
fibrinolytic agents
fibrinolytic agents,contraindications
fibrinolytic agents,utilization
fibrinolytic therapy,selection criteria
medical-legal aspects of neurology
patient information and support
review article
tissue plasminogen activator,intravenous
treatment of neurologic disorder

Click Here to return To Results